Tempest Therapeutics (TPST) Net Margin (2015 - 2018)
Tempest Therapeutics (TPST) posted Net Margin of 10325.45% for Q3 2018, down 8.58% sequentially from 9509.88% in Q2 2018, and up 640133.0% YoY from N/an in Q3 2017.
Tempest Therapeutics (TPST) Net Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported Net Margin for 4 years, with the latest figure at 10325.45% in Q3 2018.
- Quarterly Net Margin rose 640133.0% year-over-year to 10325.45% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 9959.18% (up 1013063.0% YoY) and the FY2017 annual result came in at 17279.66%, down 468242.0% from the prior year.
- Net Margin eased to 10325.45% in Q3 2018 per TPST's latest filing, from 9509.88% in the prior quarter.
- Over five years, Net Margin peaked at 9371.43% in Q4 2017 and troughed at 114706.67% in Q1 2015.
- A 4-year average of 24365.56% and a median of 14902.74% in 2016 frame the typical range for Net Margin.
- The sharpest annual moves came in 2016 and 2017: Net Margin soared 9980393 bps in 2016, then plunged 1182566 bps in 2017.
- Over 4 years, Net Margin stood at 13121.66% in 2015, then tumbled by 43 bps to 18713.22% in 2016, then surged by 50 bps to 9371.43% in 2017, then declined by 10 bps to 10325.45% in 2018.
- According to Business Quant data, Net Margin over the past three periods registered 10325.45%, 9509.88%, and 11000.0% for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -10,325.45% |
| Jun 30, 2018 | -9,509.88% |
| Mar 31, 2018 | -11,000.00% |
| Dec 31, 2017 | -9,371.43% |
| Sep 30, 2017 | -16,726.79% |
| Jun 30, 2017 | -21,650.00% |
| Mar 31, 2017 | -23,642.86% |
| Dec 31, 2016 | -18,713.22% |
| Sep 30, 2016 | -9,792.39% |
| Jun 30, 2016 | -9,824.34% |
| Mar 31, 2016 | -14,902.74% |
| Dec 31, 2015 | -13,121.66% |
| Sep 30, 2015 | -23,896.00% |
| Jun 30, 2015 | -58,300.00% |
| Mar 31, 2015 | -114,706.67% |